Crotalidae polyvalent immune Fab(ovine) - BTG

Drug Profile

Crotalidae polyvalent immune Fab(ovine) - BTG

Alternative Names: Antivenin polyvalent crotalid (Ovine) Fab - BTG; Antivenom CroTAb - BTG; CroFab; Crotalid antivenom CroTAb - BTG

Latest Information Update: 15 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Protherics
  • Developer BTG
  • Class Fab fragments; Polyvalent snake antivenins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Snake venom poisoning

Most Recent Events

  • 09 Mar 2016 BTG completes a prospective trial for Snake venom poisoning in USA
  • 09 Mar 2016 BTG initiates a prospective trial for Snake venom poisoning in USA before March 2016
  • 09 Mar 2016 Therapeutic Trial data and adverse events data from a prospective trial in Snake venom poisoning released by BTG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top